Constellation Pharmaceuticals Inc.

Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others

Plus: Barbara Handelin named co-CEO of Transformative Biotech, and updates from Zephyr AI, Venatorx, Glen Clova and more

Shift to product-focused company positioned German biotech for deal giving former Constellation assets to Swiss pharma

CEO Jean-Paul Kress leads German biotech’s pivot away from its mAb legacy

Plus: Exelixis proposes new directors amid ongoing tussle with activist investor and updates from Jasper, CIRM, Visus, Curemark and more

Plus: Lilly, Sosei in small molecule discovery deal, and updates from WuXi Biologics, Avidity, Natera, ABio, Synaptogenix and more

Plus: HotSpot, AbbVie in IRF5 collaboration and updates from Leo, MorphoSys-Novartis, Pfizer-Clear Creek  

Plus Huang becomes Zai CSO and updates from Aadi, VectorY, Fulcrum and Xenon

Plus Theolytics adds Actelion vet Oakley as CFO, and updates from Capricorn, Cambrian, 

Launched this spring with $110M, the biotech discovers small molecule and macrocyclic molecular glues using machine learning and DEL screening